Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Med Res Rev. 2018 May 4;38(6):1974–2023. doi: 10.1002/med.21503

Figure 7.

Figure 7

A) Chemical structure of β-lactam, active site inhibitor 17 of FXIa. B) The inhibition potencies (IC50 values in μM) of β-lactam 17 against a series of serine proteases. C) The acylation reaction between the β-lactam moiety of 17 and Ser195 residue of FXIa’s active site. D) The chemical structure of inhibitor 17a (Ep-7041) which just finished Phase I clinical trial.